Detalhe da pesquisa
1.
Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study.
Gynecol Oncol
; 169: 64-69, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36512912